Sequence information
DRAVP ID DRAVPc028
Name Tixagevimab
Sequence Not available
Molecular Formula C6488H10034N1746O2038S50
Condition/Disease COVID-19
Group Approved
Type Antibody
Description Tixagevimab is an extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. It is not approved for any indication by the FDA. Tixagevimab, in combination with cilgavimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended.
Active sequence/Structure
External Links
DrugBank Accession Number DB16394
Pubchem ID 434370464
CHEMBL ID Not Available
UNII F0LZ415Z3B
CAS 2420564-02-7
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT05321394 | Non-inferiority Trial on Treatments in Early COVID-19 | Coronavirus Disease 2019 (COVID‑19) Treatment | Recruiting | Phase 3 | Azienda Ospedaliera Universitaria Integrata Verona |
| NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO) | Coronavirus Disease 2019 (COVID‑19) Treatment | Active, not recruiting | Phase 3 | University of Minnesota |
| NCT04723394 | Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE) | Coronavirus Disease 2019 (COVID‑19) Treatment | Active, not recruiting | Phase 3 | AstraZeneca |
